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A protocol for a nationwide multicentre, 
prospective surveillance cohort and 
nested- consented cohort to determine 
the incidence and clinical outcomes of 
slipped capital femoral epiphysis
Aims
Slipped capital femoral epiphysis (SCFE) is one of the most common hip diseases of adoles-
cence that can cause marked disability, yet there is little robust evidence to guide treatment. 
Fundamental aspects of the disease, such as frequency, are unknown and consequently the 
desire of clinicians to undertake robust intervention studies is somewhat prohibited by a 
lack of fundamental knowledge.
Methods
The study is an anonymized nationwide comprehensive cohort study with nested consent-
ed within the mechanism of the British Orthopaedic Surgery Surveillance (BOSS) Study. All 
relevant hospitals treating SCFE in England, Scotland, and Wales will contribute anonymized 
case details. Potential missing cases will be cross- checked against two independent external 
sources of data (the national administrative data and independent trainee data). Patients 
will be invited to enrich the data collected by supplementing anonymized case data with 
patient- reported outcome measures. In line with recommendations of the IDEAL Collabora-
tion, the study will primarily seek to determine incidence, describe case mix and variations 
in surgical interventions, and explore the relationships between baseline factors (patients 
and types of interventions) and two- year outcomes.
Discussion
This is the first disease to be investigated using the BOSS Study infrastructure. It provides 
a robust method to determine the disease frequency, and a large unbiased sample of cases 
from which treatment strategies can be investigated. It may form the basis for definitive 
robust intervention studies or, where these are demonstrated not to be feasible, this may be 
the most robust cohort study.
Cite this article: Bone Joint Open 2020;1-3:35–40.
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Strengths and limitations
 This large cohort seeks to define the inci-
dence of disease, with linked national 
administrative data to identify any poten-
tially missing cases.
  This study will form a large unbiased 
sample of cases from all relevant UK 
hospitals, providing results that are 
readily generalizable.
  The study will readily be able to deter-
mine variation in practice, and provide 
key information for intervention studies.
 The study is an observational cohort 
study of standard care. Therefore, selec-
tion bias is inherent to the study design.
introduction
Slipped capital femoral epiphysis (SCFE) is the 
most common hip disease of adolescence. In 
the short- term it always requires surgery to 
stabilize the epiphysis onto the femoral neck, 
and typically results in deformity at the level 
of the growth plate. In the long- term, SCFE 
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accelerates the development of osteoarthritis, and many 
patients have disability necessitating hip arthroplasty in 
early adulthood.1 It typically presents to the clinician with 
knee, thigh or hip pain, or a limp,2 and there is strong 
evidence to suggest that obesity is the major cause.3
The incidence is reported to be approximately five to 
seven cases per 100,000 children aged six to 18 years,2,4 
though the true incidence is unknown. Estimates are 
based on hospital administrative data, in which the 
validity of the diagnoses is not confirmed.
While SCFE is the most common hip disease of adoles-
cence, robust evidence to support effective management 
and intervention is poor, with no clinical trials to guide 
treatment decisions. Administrative data are unable to be 
used to guide management, so as such databases do not 
provide detail regarding the severity and type of manage-
ment strategies, nor the clinical characteristics of the 
individual. Consequently, treatment strategies vary by 
country, by hospital, and even by surgeon. These differ-
ences have been illustrated in surveys of the membership 
of the British, Dutch, European, and north American 
Paediatric Orthopaedic Societies.5-7 The uncertainty has 
prompted members of the British Society of Children’s 
Orthopaedic Surgery to prioritize questions pertaining 
to SCFE as two of the top five research priorities across 
the whole of children’s orthopaedic surgery.8
The IDEAL Framework outlines a methodological 
approach to research in surgery.9-11 Research relating 
to SCFE has not yet reached ‘stage 2b’ within IDEAL: 
“co- operative prospective evaluation of the techniques”. 
The proposed study is a 2b design, focusing on identi-
fying the case mix, technical intervention variables, and 
clinical outcomes. The study uses the British Orthopaedic 
Surgery Surveillance (BOSS) Study, a nationwide UK 
mechanism for investigating rare orthopaedic disease, 
the basis for which is described separately, develops a 
nationwide cohort of SCFE to determine the disease inci-
dence, case mix, risk factors, variations in surgical inter-
ventions, and to determine the safety and efficacy of 
different surgical strategies.
Specific objectives
1. What is the incidence of SCFE in the UK?
2. How does incidence vary by region?
3. What is the case- mix variation (patient factors, SCFE, radi-
ological severity, and clinical stability)?
4. What is the UK variation in surgical management, and is 
this related to patient, disease, or surgeon factors (e.g. 
surgeon volume)?
5. What influence do patient, disease, and surgeon factors 
have on radiological outcomes at two years?
6. What influence do patient, disease, and surgeon factors 
have on patient- reported outcome measures (PROMs) at 
two years?
7. Is there correlation between radiological measures and 
PROMs at two years?
8. Does patient, disease, or radiological factors predict sub-
sequent contralateral disease?
Methods
A national prospective comprehensive surveillance 
cohort study of SCFE will be formed in two parts:
Anonymized surveillance cohort. A consecutive an-
onymized comprehensive cohort encompassing all UK 
cases of SCFE. Individual consent is not sought for this el-
ement of the study. In a study of a rare disorder, in which 
the number of cases is small, refusal to contribute data by 
one or two individuals will result in under- ascertainment 
of cases and incorrect calculation of incidence. Seeking 
consent would therefore reduce case ascertainment and 
introduce bias; for example, certain groups or types of 
individual might be more likely to refuse consent. The 
consecutive surveillance cohort is important to minimize 
selection bias, in accordance with recommendations of 
the IDEAL framework,9 and this method of case ascer-
tainment has been established in similar surveillance 
programmes.12,13
Consented cohort. An identified cohort formed from 
those within the surveillance cohort that consent to the 
collection of PROMs, and future data linkage.
The cohort will be collected from all UK orthopaedic 
units treating children and adolescents, with sites acting 
as data collection centres. All orthopaedic units treating 
children have agreed to participate as part of their audit 
and risk management activities, with encouragement 
from the British Orthopaedic Association, and British 
Society for Children’s Orthopaedic Surgery. This follows 
similar methodology to the successful UK Obstetric 
Surveillance Study (UKOSS).12
The study is underpinned by bespoke software that 
automates many aspects of the follow- up and communi-
cation with sites. The software is built around the REDCap 
Electronic Data Capture platform (Vanderbilt Univer-
sity, nashville, Tennessee, USA), with bespoke elements 
adding to the functionality to facilitate the study. This is 
described in detail elsewhere as the BOSS Study.
In brief, reporting clinicians upload case details 
including only minimal identifiers of individuals, 
including sex, and month and year of birth, with monthly 
electronic prompts to clinicians inviting them to confirm 
case ascertainment and to prompt follow- up. Given that 
SCFE is rare, other data sources (nationwide administra-
tive data, such as hospital episode statistics) can be peri-
odically linked to the BOSS records using the minimal 
identifiers, to identify potential missing cases at each site.
Individuals and their families will be informed about 
the BOSS Study, and will be invited to consent to provide 
patient reported outcomes to enrich the data collected. 
Patients can consent on paper at participating hospitals, 
or will be given a unique code allowing them to consent 
and participate in the study online at the study website.
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table i. ICD-10 and OPSC codes used in routine administrative data to identify cases.
Any of the following iCD-10 codes
Any of the following OPSC codes entered 
during the same admission
M93.0 Slipped capital femoral epiphysis (this ICD-10 code may be used in isolation as long as the episode of care is associated with an operation date)
M92.8 Other specified osteochondrosis AnD W241 Closed reduction of intracapsular fracture of 
neck of femur and fixation using nail or screw
M93.8 Osteochondropathy, unspecified W275 Temporary fixation of epiphysis
M93.9 Osteochondropathy W278 Other specified fixation of epiphysis
S72.0 Fracture of the neck of the femur W279 Unspecified fixation of epiphysis
Case definition
inclusions. Patients must fulfil all of the following criteria:
1. Skeletally immature individuals;
2. Radiological confirmation of displacement of the epiph-
ysis relative to the metaphysis occurring at the proximal 
femoral physis;
3. newly presenting to secondary/tertiary care during the 
study period with the above radiological changes in 
either hip (patients will be included if the other side has 
been affected outside the study period, but the opposite 
hip is newly affected);
4. Undergoing surgical stabilization during hospital admis-
sion; and
5. A resident within the England, Scotland, or Wales.
exclusions. Previous attempts at stabilization of the cur-
rently affected hip.
Denominator population. The denominator population 
will be defined as the population of children aged six to 
18 years within the geographical boundaries of England, 
Scotland, and Wales.
Potential missing cases may be identified from two 
sources; national administrative data and an indepen-
dent trainee reporting system. Potential missing cases 
are flagged to reporting clinicians each month when 
prompted to upload true cases, or to click a hyperlink to 
identify erroneous cases.
For national administrative data, cases of SCFE 
routinely undergo urgent surgery; therefore, the use 
of the data is ideal to supplement case ascertainment. 
ICD-10 codes pertaining to SCFE were identified in a prior 
study using administrative data (Table I).2 Diagnostic and 
interventional SCFE codes will be searched within the 
admission codes within the hospital episode statistics for 
England (supplied by nHS Digital), the Patient Episode 
Database for Wales, and the Scottish Morbidity Record.
Cases from administrative data will be matched to cases 
within the BOSS Study based on sex, month and year of 
birth, and date of surgery. (A seven- day window around 
the surgery date is permitted to allow for errors in coding 
within administrative datasets.) national databases are 
updated monthly, with a lead- time of three months after 
the completion of the care episode. A monthly extract 
will be sought from each of the administrative databases 
until three months after the end of case identification to 
accommodate the lead- time for data upload.
For the national Orthopaedic Surgery Trainee 
Research network, the British Orthopaedic network Envi-
ronment (BOnE) will function as a reporting network 
to highlight potential cases. If a trainee becomes aware 
of a case in the hospital where they are working, they 
will enter the date of admission, date of surgery, sex, 
and hospital trust onto a secure electronic REDCap data-
base, which is separate from the main study database. 
Data entered into the trainee’s system does not capture 
full case details and is intended to maximize recruitment 
to the main database only; data entered into the trainee 
database is not a substitute for data entered into the 
main study. At the end of each month, the trainee will 
be prompted to electronically verify that cases they have 
recorded truly reflect the activity they experienced over 
this period.
Data collected. Demographics including height and 
weight, disease chronicity and severity, surgical inter-
vention (including co- interventions), and intraoperative 
monitoring techniques (fluoroscopy/blood flow) were 
collected (Tables II and III).
The healthcare team reported the following outcomes 
at three months and two years: complications (such as 
infection, fracture, avascular necrosis, and chondolysis); 
subsequent operative interventions; planned operative 
interventions; contralateral SCFE; and radiological sphe-
ricity, measured using α angle (at two years only).
Consented cohort. Several PROMs were used, includ-
ing the Wong- Baker Faces pain rating scale, EQ- 5D- Y 
(EuroQol), and paediatric quality of life (PedsQL; Mapi 
Research Trust, Lyon, France).
The Wong- Baker Faces scale14 is a validated self- 
reported tool. It is an ordinal assessment of pain using 
a series of six facial expressions to illustrate the degree of 
pain intensity. A numerical rating is assigned to each face 
(with 0 being ‘no hurt’ to 10 being ‘hurts worst’). It has 
been validated for use among children aged over three 
years.15 It is highly correlated to the visual analogue scale 
(r = 0.90; p < 0.001). Test- retest reliability is excellent (r = 
0 .90, p < 0.001).16 The Wong- Baker scale is widely used 
in clinical practice, forming part of the Royal College of 
Emergency Medicine ‘composite tool for the assessment 
of pain in children’ produced in 2013 as part of a best 
practice guidelines.17
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table ii. Schedule of observations for the anonymized surveillance cohort.
Detail Admission 3 months postoperative 2 years postoperative
Admission for opposite sided 
SCFe at any stage
Surgeon case report (case details) X X X X
Most recently available routinely 
collected radiographs of relevant 
hip or pelvis.* (AP and lateral as per 
standard care; pre- and postoperative 
(or intraoperative if postoperative 
unavailable))
X X X
*The BOSS Study does not require that radiographs be taken for the purpose of the study. It is routine practice to undertake radiographs in the treatment 
and follow- up of SCFE. The BOSS Study requests the anonymized routinely collected images from the medical record for use by the study team.
table iii. Schedule of observations for the nested consented cohort.
Questionnaire Admission ( ± 2 weeks)
3 months  
( ± 2 weeks)
2 years (-3 months/  
+ 1 month)
Admission for opposite- 
sided SCFe ( ± 2 weeks)*
Initial admission, questions 
for parents/guardians (case 
details)
X X
EQ- 5D- Y (proxy if aged > 4 
years and < 8 years)
X X X
PedsQL (proxy if aged < 8 
years)
X X X
Wong Baker Faces Pain Scale 
(aged 4+ years)
X X X
*This will be collected if a patient already enrol in the study presents with a SCFE in the opposite hip.
EQ- 5D- Y is the youth version of the EQ- 5D- 3L, which 
is a validated, generalized, health- related quality of life 
questionnaire consisting of five domains related to daily 
activities with a three- level answer possibility. EQ- 5D- Y 
has been especially adapted in terms of language for 
children aged eight to 18  years.18,19 A proxy version is 
available for younger children. Its age appropriateness 
in terms of feasibility, reliability, and validity in children 
and adolescents has been established.19 There is currently 
ongoing work to produce EQ- 5D- Y value sets for use in 
children and adolescents. Our interim solution is to apply 
adult EQ- 5D value sets to the EQ- 5D- Y classification.
PedsQL is a well- validated, widely- used quality of life 
tool for use in children.20 It provides a general measure 
of quality of life, in addition to three summary scores, 
including a total scale score, a physical health score, and 
a psychosocial health score.
long-term follow-up. The strength of UK data linkage 
offers an efficient means for a population cohort to be 
tracked to ‘definitive outcomes’; requiring minimal intru-
sion to the patient, and minimal attrition and follow- up 
costs. Subsequent arthroplasty is regarded as ‘failure’ of 
the hip, and is therefore the definitive long- term outcome 
and can be ascertained via linkage to the national Joint 
Registry.21 Measurement is proposed after ten years, and 
at five yearly intervals. Consent will be broad for future 
linkage to healthcare and other administrative datasets, 
in line with recommendations of the recent Medical 
Research Council report concerned with maximizing the 
utility of cohorts.22
All patients entered into the surveillance cohort can 
participate in the consented cohort. Consent can be 
obtained at any time in the patient’s follow- up, but ques-
tionnaires should only be completed at the time- points 
specified in the schedule of observations.
Sample size, statistics, and analysis. Incomplete existing 
data means it is not possible to accurately predict the 
number of cases expected. national administrative data 
demonstrates an incidence of approximately five to seven 
cases per 100,000 of children aged six to 18 years.2,4 If we 
assume this approximates to the rest of the UK and use 
population data from the 2001 census (9.1 million six- to 
18- year- olds), this suggests there would be 615 annual 
new cases of SCFE (530 in England, 55 in Scotland, and 
30 in Wales). The resulting 95% Poisson confidence in-
tervals would allow the incidence to be estimated in the 
range 6.43 to 7.52 cases per 100,000 of children aged six 
to 18 years per year.
The surveillance cohort will recruit for a period of 
18  months to identify the incidence of disease. The 
nested consented cohort will require 300 cases to enable 
meaningful comparisons to be made within subgroups 
(approximately 60% of those thought to be eligible).
The full statistical analysis plan, including dummy 
tables, is available on request. Key planned analyses are 
defined as:
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1. Incidence rates will be estimated using reported new 
cases of SCFE, and denominators from UK census data. 
Rates will be stratified by country, region, age, and sex, 
and 95% confidence intervals will be calculated based on 
an assumed Poisson distribution for counts.
2. Variations in case- mix will be reported using descriptive 
statistics.
3. Variations in surgical management will be reported 
using descriptive statistics. Surgical management deci-
sions are likely to vary by hospital, patient, and disease. 
In order to better understand this process, decision trees 
will be constructed to characterize overall management 
practices and highlight variation by centre.
4. Subsequent contralateral disease in SCFE is a binary 
outcome; therefore, logistic regression will be used to 
assess the importance and quantify the effects of a range 
of patient, disease, and radiological risks factors on this 
outcome, after adjusting for known confounders; recur-
sive partitioning will be used to understand the most 
likely combinations of subgroups of baseline factors in 
predicting contralateral SCFE. Time to contralateral SCFE 
will be displayed using Kaplan- Meier plots, overall and 
split by age group and sex.
5. Univariate and multivariate analyses including random 
effects will be used to explore the relationship between 
baseline factors and two- year outcomes. Logistic regres-
sion for binary outcomes (such as AVn), and linear 
regression for continuous outcomes (e.g. α angle and 
two- year PROMs).
6. Associations between hip shape and PROMs at two years 
will be quantified using Spearman’s rank r and displayed 
with scatterplots.
ethical considerations and approval
The ethical approach for the anonymized surveillance 
study has broadly been described elsewhere.
Among those entering the consented study, informed 
written/electronic consent will be obtained from parents 
or legal guardians (if participants are younger than 
16 years). Patients who become aged 16 years while in 
the study will be asked to provide a written/electronic 
consent to affirm their willingness to continue participa-
tion in the study.
Assent will be sought from competent minors over 
eight years of age, where the research team assesses 
competence and relevance to do so. Where possible, the 
minor should personally write their name and date the 
assent form themselves. The form is then countersigned 
by the parent/legal representative and the researcher 
taking consent. Assent forms do not substitute for the 
consent form. Assent should be taken where appropriate; 
however, the absence of assent does not exclude the 
patient from the study if consent has been obtained from 
the parent/legal representative.
This programme of work complies with the Helsinki 
Declaration and was reviewed and approved by the 
national Research Ethics Service Committee London 
– City and East (REC ref 15/LO/2202) and the Health 
Research Authority (ref 190754). The release of national 
administrative data for this purpose was approved by 
the Public Benefit and Privacy Panel (PBPP) in Scotland 
(ref - 1617 to 0030) and the Data Access Advisory Group 
(DAAG) in England (ref nIC-362142- K9C7P). There was 
no similar process in Wales.
Patient and public involvement
Representatives of Steps UK, the primary charitable 
support group for children and young people with 
limb disorders, were consulted in the development of 
the funding application for this programme of work. 
Members of this group will sit on the study management 
group. The national Institute for Health Research Young 
Person’s Advisory Group, a group of children and young 
people involved in improving the conduct of research in 
children, assisted in the development of the participant 
information materials.
Discussion
The framework proposed by the IDEAL collaboration 
forms the basis for the study.9 The evidence in the treat-
ment of SCFE is such that the current evidence is not 
mature enough to support the development of random-
ized clinical trials. The intention of this large surveillance 
cohort and nested- consented cohort is to provide robust 
feasibility data for randomized trials, and if such trials are 
not feasible, then the intention is that this will form the 
definitive cohort.
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